7464-09-7

Usage

Uses

Used in Pharmaceutical Industry:
Thiazolo[4,5-d]pyrimidine-5,7-diol is utilized as a lead compound in drug discovery for its potential to treat various diseases such as cancer, inflammation, and neurodegenerative disorders. Its unique structure and properties allow it to interact with biological targets, offering new avenues for the development of therapeutic agents.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, thiazolo[4,5-d]pyrimidine-5,7-diol serves as a valuable subject of study. Researchers investigate its interactions with biological systems to understand its mechanisms of action and to optimize its therapeutic potential, with the aim of creating more effective and safer drugs.
Used in Drug Development:
Thiazolo[4,5-d]pyrimidine-5,7-diol is employed in the process of drug development as a template for designing new pharmaceuticals. Its heterocyclic structure provides a foundation for chemical modifications that can enhance its pharmacological properties, such as potency, selectivity, and bioavailability, making it a versatile component in the creation of novel therapeutic agents.

InChI:InChI=1/C5H3N3O2S/c9-4-2-3(6-1-11-2)7-5(10)8-4/h1H,(H2,7,8,9,10)

Upstream product

• 7464-10-0 thiazole-4,5-dicarboxylic acid diamide 
• 57-13-6 urea 
• 278183-10-1 methyl 4-amino-1,3-thiazole-5-carboxylatte 
• 30161-92-3 2-chloro-4H-thiazolo[4,5-d]pyrimidine-5,7-dione 
• 30161-91-2 2-amino-4H-thiazolo[4,5-d]pyrimidine-5,7-dione 
• 23126-24-1 6-amino-5-thiocyanato-1H-pyrimidine-2,4-dione 

Downstream Products

• 28969-60-0 4-amino-2,5,6-trichloropyrimidine 

Relevant academic research and scientific papers

Preparation method of 5-bromine-thiazolo [4,5-D] pyrimidine

The invention discloses a preparation method of 5-bromine-thiazolo [4,5-D] pyrimidine. The preparation method comprises the following specific steps of by adopting 4-amino-5-thiazolecarboxylate as an initial material, preparing thiazolo [4,5-D] pyrimidine-5,7-glycol through cyclization; preparing thiazolo [4,5-D] pyrimidine-5,7-dibromo from the thiazolo [4,5-D] pyrimidine-5,7-glycol through bromination reaction; and finally preparing 5-bromine-thiazolo [4,5-D] pyrimidine from the thiazolo [4,5-D] pyrimidine-5,7-dibromo through hydrogenation. The method is short in process route, convenient to operate, relatively mild in reaction condition, easy to control, relatively low in cost and suitable for process amplification, and a product is easy to purify and relatively high in yield.

TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES

The invention relates to novel therapeutic agents and diagnostic probes. The invention also relates to phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor triazine-, pyrimidine- and pyridine-based compounds^ Formula (I), their stereoisomers, geometric isomers, tautomers, solvates, metabolites, N-oxide derivatives, pharmaceutically acceptable salts, and prodrugs thereof compositions of the new compounds; either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, for treating disorders mediated by lipid kinases. ?Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis,.prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. (Formula I)

THIAZOLOPYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE

Compounds of Formulas (Ia and Ib), and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of formula Ia and Ib for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed